The sweet tooth of biopharmaceuticals: Importance of recombinant protein glycosylation analysis

Biotechnology Journal

Volumn 7, Issue 12, 2012, Pages 1462-1472

  Lingg, Nico ^a,b   Zhang, Peiqing ^a   Song, Zhiwei ^a   Bardor, Muriel ^a  

^a AGENCY FOR SCIENCE   (Singapore)

^b UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

Analytical biotechnology; Carbohydrates; Chromatography; Mass spectrometry; Recombinant proteins

Indexed keywords

ANALYTICAL METHOD; BIOPHARMACEUTICALS; CRITICAL QUALITY; ERYTHROPOIETIN (EPO); GLUCOCEREBROSIDASE; GLYCOSYLATION OF RECOMBINANT PROTEINS; PHARMACEUTICAL INDUSTRY; POST-TRANSLATIONAL MODIFICATIONS; PROTEIN DRUGS; PROTEIN GLYCOSYLATION; QUALITY TARGETS; QUANTITATIVE MEASUREMENT; RAPID EXPANSION; RECOMBINANT GLYCOPROTEINS;

AUTOMOBILE MANUFACTURE; CARBOHYDRATES; CHROMATOGRAPHY; ESTERIFICATION; GLYCOPROTEINS; GLYCOSYLATION; MASS SPECTROMETRY; PRODUCT DESIGN; RECOMBINANT PROTEINS;

QUALITY CONTROL;

ERYTHROPOIETIN; GLUCOSYLCERAMIDASE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT PROTEIN; SIALIC ACID;

BINDING AFFINITY; CARBOHYDRATE ANALYSIS; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG INDUSTRY; DRUG MANUFACTURE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; ISOELECTRIC FOCUSING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHARMACEUTICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN INTERACTION; QUALITATIVE ANALYSIS; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVIEW; WORKFLOW;

BIOPHARMACEUTICS; BIOTECHNOLOGY; CHROMATOGRAPHY; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; MASS SPECTROMETRY; RECOMBINANT PROTEINS;

EID: 84870698615     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201200078     Document Type: Review

References (99)

1. Leader, B., Baca, Q. J., Golan, D. E., Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 2008, 7, 21-39.
2. Walsh, G., Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 2010, 28, 917-924.
3. Ratner, M., Pharma swept up in biogenerics gold rush. Nat. Biotechnol. 2009, 27, 299-301.
4. Higgins, E., Carbohydrate analysis throughout the development of a protein therapeutic. Glycoconjugate J. 2010, 27, 211-225.
5. Stanley, P., Schachter, H., Taniguchi, N., Chapter 8: N-Glycans, in: Varki, A., Cummings, R., Esko, J., Freeze, H. et al. (Eds.), Essentials of Glycobiology, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 2009, pp. 101-114.
6. Jiang, X. R., Song, A., Bergelson, S., Arroll, T. et al., Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat. Rev. Drug Discov. 2011, 10, 101-111.
7. Pandhal, J., Wright, P., N-Linked glycoengineering for human therapeutic proteins in bacteria. Biotechnol. Lett. 2010, 32, 1189-1198.
8. Sola, R. J., Griebenow, K., Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs 2010, 24, 9-21.
9. Brooks, S. A., Chapter 1: An introduction to human N- and O-linked protein glycosylation, in: Brooks, S., Rudd, P., Appelmelk, B. (Eds.), Glycosylation in Diverse Cell Systems: Challenges and New Frontiers in Experimental Biology, Society for Experimental Biology, London, UK 2011, pp. 1-24.
10. Hossler, P., Khattak, S. F., Li, Z. J., Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 2009, 19, 936-949.
11. International conference on harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products. Notice. Food and Drug Administration, HHS. Fed. Regist. 1999, 64, 44928-44935.
12. International conference on harmonisation; guidance on Q5E comparability of biotechnological/biological products subject to changes in their manufacturing process; availability. Notice. Fed. Regist. 2005, 70, 37861-37862.
13. Fernandes, D., Comparability of biopharmaceutical glycosylation during scale-up. Biopharm International 2011, 44-50, 52-53.
14. Beck, A., Wurch, T., Bailly, C., Corvaia, N., Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 2010, 10, 345-352.
15. Scolnik, P. A., mAbs: A business perspective. mAbs 2009, 1, 179-184.
16. Jefferis, R., Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 2009, 8, 226-234.
17. Beck, A., Wagner-Rousset, E., Bussat, M.-C., Lokteff, M. et al., Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr. Pharm. Biotechnol. 2008, 9, 482-501.
18. Rudd, P. M., Elliott, T., Cresswell, P., Wilson, I. A., Dwek, R. A., Glycosylation and the immune system. Science 2001, 291, 2370-2376.
19. Anthony, R. M., Ravetch, J. V., A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Immunol. 2010, 30, 1, S9-14.
20. Peipp, M., Lammerts van Bueren, J. J., Schneider-Merck, T., Bleeker, W. W. K. et al., Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 2008, 112, 2390-2399.
21. Kanda, Y., Yamada, T., Mori, K., Okazaki, A. et al., Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 2007, 17, 104-118.
22. Hodoniczky, J., Zheng, Y. Z., James, D. C., Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol. Prog. 2005, 21, 1644-1652.
23. Houde, D., Peng, Y., Berkowitz, S. A., Engen, J. R., Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol. Cell. Proteomics 2010, 9, 1716-1728.
24. Davies, J., Jiang, L., Pan, L.-Z., LaBarre, M. J. et al., Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FCγRIII. Biotechnol. Bioeng. 2001, 74, 288-294.
25. Scallon, B. J., Tam, S. H., McCarthy, S. G., Cai, A. N., Raju, T. S., Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol. Immunol. 2007, 44, 1524-1534.
26. Kaneko, Y., Nimmerjahn, F., Ravetch, J. V., Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313, 670-673.
27. Jefferis, R., Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol. Sci. 2009, 30, 356-362.
28. Reichel, C., Gmeiner, G., Erythropoietin and analogs. Handb. Exp. Pharmacol. 2010, 251-294.
29. Wasley, L. C., Timony, G., Murtha, P., Stoudemire, J. et al., The importance of N- and O-linked oligosaccharides for the biosynthesis and in vitro and in vivo biologic activities of erythropoietin. Blood 1991, 77, 2624-2632.
30. Fukuda, M. N., Sasaki, H., Lopez, L., Fukuda, M., Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 1989, 73, 84-89.
31. Martin, K. J., The first human cell line-derived erythropoietin, epoetin-delta (Dynepo), in the management of anemia in patients with chronic kidney disease. Clin Nephrol 2007, 68, 26-31.
32. Hokke, C. H., Bergwerff, A. A., Van Dedem, G. W., Kamerling, J. P., Vliegenthart, J. F., Structural analysis of the sialylated N- and O-linked carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. Sialylation patterns and branch location of dimeric N-acetyllactosamine units. Eur. J. Biochem. 1995, 228, 981-1008.
33. Shahrokh, Z., Royle, L., Saldova, R., Bones, J. et al., Erythropoietin produced in a human cell line (Dynepo) has significant differences in glycosylation compared with erythropoietins produced in CHO cell lines. Mol. Pharm. 2011, 8, 286-296.
34. Nimtz, M., Wray, V., Rudiger, A., Conradt, H. S., Identification and structural characterization of a mannose-6-phosphate containing oligomannosidic N-glycan from human erythropoietin secreted by recombinant BHK-21 cells. FEBS Lett. 1995, 365, 203-208.
35. Park, S. S., Park, J., Ko, J., Chen, L. et al., Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen. J. Pharm. Sci. 2009, 98, 1688-1699.
36. Berg-Fussman, A., Grace, M. E., Ioannou, Y., Grabowski, G. A., Human acid beta-glucosidase. N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity. J. Biol. Chem. 1993, 268, 14861-14866.
37. Weinreb, N. J., Imiglucerase and its use for the treatment of Gaucher's disease. Expert Opin. Pharmacother. 2008, 9, 1987-2000.
38. Brumshtein, B., Salinas, P., Peterson, B., Chan, V. et al., Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology 2010, 20, 24-32.
39. Shaaltiel, Y., Bartfeld, D., Hashmueli, S., Baum, G. et al., Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol. J. 2007, 5, 579-590.
40. Tarp, M. A., Clausen, H., Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim. Biophys. Acta 2008, 1780, 546-563.
41. Springer, G. F., T and Tn, general carcinoma autoantigens. Science 1984, 224, 1198-1206.
42. Hermeling, S., Crommelin, D. J., Schellekens, H., Jiskoot, W., Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 2004, 21, 897-903.
43. Nimtz, M., Martin, W., Wray, V., Kloppel, K. D. et al., Structures of sialylated oligosaccharides of human erythropoietin expressed in recombinant BHK-21 cells. Eur. J. Biochem. 1993, 213, 39-56.
44. Inoue, N., Takeuchi, M., Asano, K., Shimizu, R. et al., Structures of mucin-type sugar chains on human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells. Arch. Biochem. Biophys. 1993, 301, 375-378.
45. Wandall, H. H., Blixt, O., Tarp, M. A., Pedersen, J. W. et al., Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res. 2010, 70, 1306-1313.
46. Blixt, O., Bueti, D., Burford, B., Allen, D. et al., Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res. 2011, 13, R25.
47. Muller, S., Hanisch, F. G., Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin. High density and prevalent core 2-based glycosylation. J. Biol. Chem. 2002, 277, 26103-26112.
48. Olson, F. J., Backstrom, M., Karlsson, H., Burchell, J., Hansson, G. C., A MUC1 tandem repeat reporter protein produced in CHO-K1 cells has sialylated core 1 O-glycans and becomes more densely glycosylated if coexpressed with polypeptide-GalNAc-T4 transferase. Glycobiology 2005, 15, 177-191.
49. Engelmann, K., Baldus, S. E., Hanisch, F. G., Identification and topology of variant sequences within individual repeat domains of the human epithelial tumor mucin MUC1. J. Biol. Chem. 2001, 276, 27764-27769.
50. Muller, S., Alving, K., Peter-Katalinic, J., Zachara, N. et al., High density O-glycosylation on tandem repeat peptide from secretory MUC1 of T47D breast cancer cells. J. Biol. Chem. 1999, 274, 18165-18172.
51. Morelle, W., Faid, V., Chirat, F., Michalski, J. C., Analysis of N- and O-linked glycans from glycoproteins using MALDI-TOF mass spectrometry. Methods Mol. Biol. 2009, 534, 5-21.
52. Hanisch, F. G., Teitz, S., Schwientek, T., Muller, S., Chemical de-O-glycosylation of glycoproteins for application in LC-based proteomics. Proteomics 2009, 9, 710-719.
53. Kozak, R. P., Royle, L., Gardner, R. A., Fernandes, D. L., Wuhrer, M., Suppression of peeling during the release of O-glycans by hydrazinolysis. Anal. Biochem. 2012, 423, 119-128.
54. Yu, G., Zhang, Y., Zhang, Z., Song, L. et al., Effect and limitation of excess ammonium on the release of O-glycans in reducing forms from glycoproteins under mild alkaline conditions for glycomic and functional analysis. Anal. Chem. 2010, 82, 9534-9542.
55. Yamada, K., Hyodo, S., Matsuno, Y. K., Kinoshita, M. et al., Rapid and sensitive analysis of mucin-type glycans using an in-line flow glycan-releasing apparatus. Anal. Biochem. 2007, 371, 52-61.
56. Wada, Y., Dell, A., Haslam, S. M., Tissot, B. et al., Comparison of methods for profiling O-glycosylation: HUPO human disease glycomics/proteome initiative multi-institutional study of IgA1. Mol. Cell. Proteomics 2010, 9, 719-727.
57. Lasne, F., de Ceaurriz, J., Recombinant erythropoietin in urine. Nature 2000, 405, 635.
58. Hansler, M., Kotz, K., Hantzschel, H., Detection of immunoglobulin G glycosylation changes in patients with rheumatoid arthritis by means of isoelectric focusing and lectin-affinoblotting. Electrophoresis 1995, 16, 811-812.
59. Zhang, P., Tan, D. L., Heng, D., Wang, T. et al., A functional analysis of N-glycosylation-related genes on sialylation of recombinant erythropoietin in six commonly used mammalian cell lines. Metab. Eng. 2010, 12, 526-536.
60. Lasne, F., Martin, L., Crepin, N., de Ceaurriz, J., Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Anal. Biochem. 2002, 311, 119-126.
61. Chuan, K. H., Lim, S. F., Martin, L., Yun, C. Y. et al., Caspase activation, sialidase release and changes in sialylation pattern of recombinant human erythropoietin produced by CHO cells in batch and fed-batch cultures. Cytotechnology 2006, 51, 67-79.
62. Warren, L., The thiobarbituric acid assay of sialic acids. J. Biol. Chem. 1959, 234, 1971-1975.
63. Markely, L. R., Ong, B. T., Hoi, K. M., Teo, G. et al., A high-throughput method for quantification of glycoprotein sialylation. Anal Biochem 2010, 407, 128-133.
64. Tangvoranuntakul, P., Gagneux, P., Diaz, S., Bardor, M. et al., Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc. Natl. Acad. Sci. USA 2003, 100, 12045-12050.
65. Klein, A., Diaz, S., Ferreira, I., Lamblin, G. et al., New sialic acids from biological sources identified by a comprehensive and sensitive approach: liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) of SIA quinoxalinones. Glycobiology 1997, 7, 421-432.
66. Ghaderi, D., Taylor, R. E., Padler-Karavani, V., Diaz, S., Varki, A., Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat. Biotechnol. 2010, 28, 863-867.
67. Harazono, A., Kobayashi, T., Kawasaki, N., Itoh, S. et al., A comparative study of monosaccharide composition analysis as a carbohydrate test for biopharmaceuticals. Biologicals 2011, 39, 171-180.
68. Rohrer, J. S., Thayer, J., Weitzhandler, M., Avdalovic, N., Analysis of the N-acetylneuraminic acid and N-glycolylneuraminic acid contents of glycoproteins by high-pH anion-exchange chromatography with pulsed amperometric detection (HPAEC/PAD). Glycobiology 1998, 8, 35-43.
69. Cataldi, T. R. I., Campa, C., De Benedetto, G. E., Carbohydrate analysis by high-performance anion-exchange chromatography with pulsed amperometric detection: The potential is still growing. Fresenius' Journal of Anal. Chem. 2000, 368, 739-758.
70. Triguero, A., Cabrera, G., Royle, L., Harvey, D. J. et al., Chemical and enzymatic N-glycan release comparison for N-glycan profiling of monoclonal antibodies expressed in plants. Anal. Biochem. 2010, 400, 173-183.
71. Anumula, K. R., Advances in fluorescence derivatization methods for high-performance liquid chromatographic analysis of glycoprotein carbohydrates. Anal. Biochem. 2006, 350, 1-23.
72. Ruhaak, L., Zauner, G., Huhn, C., Bruggink, C. et al., Glycan labeling strategies and their use in identification and quantification. Analytical and BioAnal. Chem. 2010, 397, 3457-3481.
73. Melmer, M., Stangler, T., Schiefermeier, M., Brunner, W. et al., HILIC analysis of fluorescence-labeled N-glycans from recombinant biopharmaceuticals. Anal. Bioanal. Chem. 2010, 398, 905-914.
74. Séveno, M., Cabrera, G., Triguero, A., Burel, C. et al., Plant N-glycan profiling of minute amounts of material. Anal. Biochem. 2008, 379, 66-72.
75. Chen, X., Flynn, G. C., Analysis of N-glycans from recombinant immunoglobulin G by on-line reversed-phase high-performance liquid chromatography/mass spectrometry. Anal. Biochem. 2007, 370, 147-161.
76. Gilar, M., Yu, Y.-Q., Ahn, J., Xie, H. et al., Characterization of glycoprotein digests with hydrophilic interaction chromatography and mass spectrometry. Anal. Biochem. 2011, 417, 80-88.
77. Ahn, J., Bones, J., Yu, Y. Q., Rudd, P. M., Gilar, M., Separation of 2-aminobenzamide labeled glycans using hydrophilic interaction chromatography columns packed with 1.7 [mu]m sorbent. J. Chromatogr. B 2010, 878, 403-408.
78. Bones, J., McLoughlin, N., Hilliard, M., Wynne, K. et al., 2D-LC analysis of BRP 3 erythropoietin N-glycosylation using anion exchange fractionation and hydrophilic interaction UPLC reveals long poly-N-acetyl lactosamine extensions. Anal. Chem. 2011, 83, 4154-4162.
79. Melmer, M., Stangler, T., Premstaller, A., Lindner, W., Comparison of hydrophilic-interaction, reversed-phase and porous graphitic carbon chromatography for glycan analysis. J. Chromatogr. A 2011, 1218, 118-123.
80. Grey, C., Edebrink, P., Krook, M., Jacobsson, S. P., Development of a high performance anion exchange chromatography analysis for mapping of oligosaccharides. J. Chromatogr. B 2009, 877, 1827-1832.
81. Ceaglio, N., Etcheverrigaray, M., Conradt, H. S., Grammel, N. et al., Highly glycosylated human alpha interferon: sn insight into a new therapeutic candidate. J. Biotechnol. 2010, 146, 74-83.
82. Davies, M. J., Hounsell, E. F., Carbohydrate chromatography: towards yoctomole sensitivity. Biomed. Chromatogr. 1996, 10, 285-289.
83. Mechref, Y., Novotny, M. V., Structural investigations of glycoconjugates at high sensitivity. Chem. Rev. 2002, 102, 321-369.
84. Wada, Y., Azadi, P., Costello, C. E., Dell, A. et al., Comparison of the methods for profiling glycoprotein glycans - HUPO human disease glycomics/proteome initiative multi-institutional study. Glycobiology 2007, 17, 411-422.
85. Kang, P., Mechref, Y., Kyselova, Z., Goetz, J. A., Novotny, M. V., Comparative glycomic mapping through quantitative permethylation and stable-isotope labeling. Anal. Chem. 2007, 79, 6064-6073.
86. Harvey, D. J., Quantitative aspects of the matrix-assisted laser desorption mass spectrometry of complex oligosaccharides. Rapid Commun. Mass Spectrom. 1993, 7, 614-619.
87. Takegawa, Y., Ito, S., Yoshioka, S., Deguchi, K. et al., Structural assignment of isomeric 2-aminopyridine-derivatized oligosaccharides using MSn spectral matching. Rapid Commun. Mass Spectrom. 2004, 18, 385-391.
88. Zaia, J., Mass spectrometry and glycomics. OMICS 2010, 14, 401-418.
89. Ritchie, G., Harvey, D. J., Stroeher, U., Feldmann, F. et al., Identification of N-glycans from Ebola virus glycoproteins by matrix-assisted laser desorption/ionisation time-of-flight and negative ion electrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom.
90. Pabst, M., Altmann, F. et al., Glycan analysis by modern instrumental methods. Proteomics 2011, 11, 631-643.
91. Harvey, D. J., Rudd, P. M., Fragmentation of negative ions from N-linked carbohydrates. Part 5: Anionic N-linked glycans. Int. J. Mass Spectrom. 2011, 305, 120-130.
92. Kawasaki, N., Ohta, M., Hyuga, S., Hyuga, M., Hayakawa, T., Application of liquid chromatography/mass spectrometry and liquid chromatography with tandem mass spectrometry to the analysis of the site-specific carbohydrate heterogeneity in erythropoietin. Anal. Biochem. 2000, 285, 82-91.
93. Bardor, M., Loutelier-Bourhis, C., Paccalet, T., Cosette, P. et al., Monoclonal C5-1 antibody produced in transgenic alfalfa plants exhibits a N-glycosylation that is homogenous and suitable for glyco-engineering into human-compatible structures. Plant Biotechnol. J. 2003, 1, 451-462.
94. Xie, H., Doneanu, C., Chen, W., Rininger, J., Mazzeo, J. R., Characterization of a recombinant influenza vaccine candidate using complementary LC-MS methods. Curr. Pharm. Biotechnol. 2011, 12, 1568-1579.
95. Harrison, R., Hitchen, P. G., Panico, M., Morris, H. R. et al., Glycoproteomic characterization of recombinant mouse alpha-dystroglycan. Glycobiology 2012, 22, 662-675.
96. Pandhal, J., Ow, S. Y., Noirel, J., Wright, P. C., Improving N-glycosylation efficiency in Escherichia coli using shotgun proteomics, metabolic network analysis, and selective reaction monitoring. Biotechnol. Bioeng. 2011, 108, 902-912.
97. Kaji, H., Yamauchi, Y., Takahashi, N., Isobe, T., Mass spectrometric identification of N-linked glycopeptides using lectin-mediated affinity capture and glycosylation site-specific stable isotope tagging. Nat. Protoc. 2006, 1, 3019-3027.
98. Wuhrer, M., Koeleman, C. A., Hokke, C. H., Deelder, A. M., Protein glycosylation analyzed by normal-phase nano-liquid chromatography-mass spectrometry of glycopeptides. Anal. Chem. 2005, 77, 886-894.
99. Wuhrer, M., Catalina, M. I., Deelder, A. M., Hokke, C. H., Glycoproteomics based on tandem mass spectrometry of glycopeptides. J. Chromatogr. B 2007, 849, 115-128.